Emergent BioSolutions Inc.
EBS NYSE
SEC CIK 1367644
Follow Emergent BioSolutions
Weekly email: filings, results
Revenue, last quarter
$110M
−52.4% vs same quarter last year
Net income
−$32.7M
−163.9% vs same quarter last year
EPS, diluted
−$0.64
−170.3% vs same quarter last year
Operating cash flow
$100.1M
+4452.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $742.9M | $52.6M |
| FY24 | $1B | −$190.6M |
| FY23 | $1B | −$760.5M |
| FY22 | $1.1B | −$211.6M |
| FY21 | $1.8B | $219.5M |
| FY20 | $1.6B | $305.8M |
| FY19 | $1.1B | $54.5M |
| FY18 | $782.4M | $62.7M |
| FY17 | $560.9M | $82.6M |
| FY16 | $488.8M | $51.8M |
| FY15 | $522.8M | $62.9M |
| FY14 | $450.1M | $36.7M |
| FY13 | $312.7M | $31.1M |
| FY12 | $281.9M | $23.5M |
| FY11 | $273.4M | $23M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 56.1% | 13.5% | 7.1% |
| FY24 | 34.7% | −10.4% | −18.3% |
| FY23 | 30.3% | −69.2% | −72.5% |
| FY22 | 34.3% | −15.2% | −18.9% |
| FY21 | 50.3% | 19.2% | 12.4% |
| FY20 | 59.5% | 28.2% | 19.7% |
| FY19 | 60.8% | 10.3% | 4.9% |
| FY18 | 58.8% | 11.5% | 8% |
| FY17 | 66.5% | 22.2% | 14.7% |
| FY16 | 74.2% | 21.6% | 10.6% |
| FY15 | 79.4% | 27.1% | 12% |
| FY14 | 77.3% | 19.8% | 8.2% |
| FY13 | 80.1% | 13.7% | 10% |
| FY12 | 83.7% | 10.6% | 8.3% |
| FY11 | 84.6% | 11.7% | 8.4% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $156.8M |
| FY24 | $35.8M |
| FY23 | −$257.9M |
| FY22 | −$149.9M |
| FY21 | $96.1M |
| FY20 | $395M |
| FY19 | $101.1M |
| FY18 | −$30.3M |
| FY17 | $153.3M |
| FY16 | −$21.6M |
| FY15 | −$2.3M |
| FY14 | $81.6M |
| FY13 | $54.9M |
| FY12 | −$14.2M |
| FY11 | −$41.8M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $24.9M |
| FY24 | $0 |
| FY23 | $0 |
| FY22 | $82.1M |
| FY21 | $106M |
| FY20 | $0 |
| FY19 | $0 |
| FY18 | $100K |
| FY17 | $33.1M |
| FY16 | $0 |
| FY15 | $100K |
| FY14 | $200K |
| FY13 | $213K |
| FY12 | $5.9M |
| FY11 | $0 |
- Emergent BioSolutions
- Healthcare median
Show the numbers
| Year | Emergent BioSolutions | Healthcare median |
|---|---|---|
| FY25 | 7.1% | −30.6% |
| FY24 | −18.3% | −47% |
| FY23 | −72.5% | −58% |
| FY22 | −18.9% | −80.4% |
| FY21 | 12.4% | −71.9% |
| FY20 | 19.7% | −62.2% |
| FY19 | 4.9% | −46.3% |
| FY18 | 8% | −49.6% |
| FY17 | 14.7% | −45.9% |
| FY16 | 10.6% | −36% |
| FY15 | 12% | −38.4% |
| FY14 | 8.2% | −35.5% |
| FY13 | 10% | −37.1% |
| FY12 | 8.3% | −29.1% |
| FY11 | 8.4% | −27.9% |